Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study

Figure 2

A. Kaplan–Meier analysis was used to evaluate overall survival in tamoxifen (TAM) or toremifene (TOR) treated premenopausal breast cancer patients ( p= 0.087). B. Kaplan–Meier analysis was used to evaluate recurrence-free survival in tamoxifen (TAM) or toremifene (TOR) treated premenopausal breast cancer patients (p = 0.022).

Back to article page